Contineum Therapeutics (NASDAQ:CTNM) Trading Up 13.5%

Contineum Therapeutics, Inc. (NASDAQ:CTNM)’s share price shot up 13.5% on Monday . The company traded as high as $19.99 and last traded at $19.99. 20,679 shares traded hands during trading, a decline of 78% from the average session volume of 93,366 shares. The stock had previously closed at $17.61.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Morgan Stanley initiated coverage on Contineum Therapeutics in a research note on Tuesday, April 30th. They issued an “overweight” rating and a $25.00 target price on the stock. Stifel Nicolaus initiated coverage on shares of Contineum Therapeutics in a research report on Tuesday, April 30th. They set a “buy” rating and a $29.00 target price on the stock. Finally, Royal Bank of Canada started coverage on shares of Contineum Therapeutics in a research note on Tuesday, April 30th. They issued an “outperform” rating and a $30.00 price objective for the company.

Contineum Therapeutics Stock Down 1.5 %

The stock’s 50 day moving average is $16.53.

Contineum Therapeutics (NASDAQ:CTNM) last released its quarterly earnings results on Thursday, May 16th. The company reported ($3.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($3.02). As a group, analysts predict that Contineum Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).